At 4mg weekly, each injection is approximately 1.14mg, given that you inject 3.5 times per week on average
The approach depends on how many days have elapsed since the scheduled injection
Key timing considerations: Broader Tmax window (8 to 72 hours) means less precision in predicting peak effects Dual GIP/GLP-1 mechanism may produce a different side effect timing pattern than pure GLP-1 agonists Body aches and muscle pain may peak later than GI symptoms, around 24 to 48 hours post-injection Consider how tirzepatide affects metabolism throughout the weekly cycle The appetite suppression timeline may differ from semaglutide due to the dual mechanism Dose escalation timing: Tirzepatide starts at 2.5mg weekly, escalating to 5mg after 4 weeks
Tirzepatide dual-agonist therapy engages both GLP-1 and GIP receptors, producing weight loss outcomes superior to semaglutide monotherapy in randomized trials
Nakamura T, Ito T, Uchida M, Hijioka M, Igarashi H, Oono T, Kato M, Nakamura K, Suzuki K, Jensen RT, and Takayanagi R
This method is preferred over intramuscular injections due to its ease of administration and reduced risk of impacting blood vessels or nerves
